Orion - Changes in company's own shares

Orion Corporation completed share acquisitions

ORION CORPORATION      STOCK EXCHANGE RELEASE 15 JUNE 2016 at 18.40
EEST


Orion Corporation completed share acquisitions

The share acquisitions announced by Orion Corporation on 27 April 2016 have been
completed. The Company has purchased during the time period from 3 June 2016 to
15 June 2016 through public trading in accordance with the rules of on the
Nasdaq Helsinki Ltd. a total of 500,000 Company's own B shares at an average
price per share of approximately EUR 33.5319. The total purchase price paid for
the shares was EUR 16,765,946.50.

After the repurchases, the Company holds a total of 783,366 own B shares
corresponding to approximately 0.55% of the total number of the shares and
0.09% of the votes.



Orion Corporation



 Timo Lappalainen    Olli Huotari
 President and CEO   SVP, Corporate Functions




Contact person:
Tuukka Hirvonen, Communications Manager, Financial Communications & Investor
Relations
tel. +358 10 426 2721



Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. The core therapy areas of Orion's pharmaceutical R&D are
central nervous system (CNS) disorders, oncology and respiratory for which Orion
developes inhaled Easyhaler® pulmonary drugs.

Orion's net sales in 2015 amounted to EUR 1,016 million and the Company had
about 3,400 employees. Orion's A and B shares are listed on Nasdaq Helsinki.

[HUG#2020874]